Ignite Creation Date:
2025-12-24 @ 9:45 PM
Ignite Modification Date:
2026-01-01 @ 5:22 PM
Study NCT ID:
NCT00098332
Status:
COMPLETED
Last Update Posted:
2013-07-10
First Post:
2004-12-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
Sponsor:
BioCryst Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
BIOCRYST-BCX1777-C-04-105
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None